Allakos — Investor Presentation (October 2024)
27 slides from Allakos's investor presentation, Oct 10, 2024
Slide 1: Corporate Presentation October 2024
Corporate Presentation October 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); estimated lirentelimab closeout,
Slide 3: Allakos Opportunity
Allakos Opportunity Novel Target Milestones Early Q1’25 – Report topline Phase 1 data of AK006 in patients with CSU AK006 (anti-Siglec-6 mAb) selectively inhibits multiple modes of mast cell activation Inhibits IgE-dependent and IgE-independent mast cell activation pathways, including IgE, KIT and M
Slide 4: Mast Cells Are Key Drivers of Inflammatory Disease
Mast Cells Are Key Drivers of Inflammatory Disease IL-13
Slide 5: Mast Cells Play a Significant Role in Many Diseases
Mast Cells Play a Significant Role in Many Diseases
Slide 6: Leveraging the Native Inhibitory Function of Siglecs on Mast Cells
Leveraging the Native Inhibitory Function of Siglecs on Mast Cells Activated State Siglec-Mediated Inhibition Mast cells can be activated by numerous receptors leading to mast cell degranulation and release of histamine, TNFα and other inflammatory mediators Activation of Siglec-6 with an agonistic
Slide 7: Allakos Pipeline
Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Milestone AK006 (Anti-Siglec-6) Healthy Volunteers & CSU CSU results expected early Q1’25 AK068 (Siglec-6/Siglec-8 Bispecific) Inflammatory Diseases Ongoing Undisclosed Inflammatory Diseases Ongoing Allakos Pipeline
Slide 8: AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells
AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells
Slide 9: Siglec-6 Is Selectively Expressed on Human Tissue Mast Cells
Siglec-6 Is Selectively Expressed on Human Tissue Mast Cells Gating Strategy for Immune Cells in Human Tissue Siglec-6 Expression Profile Siglec-6 represents a selective mast cell inhibitory receptor n=15 human donors SOURCE: Allakos data on file
Slide 10: AK006 Mechanism of Action
AK006 was Designed to Activate the Native Function of Siglec-6 AK006 Mechanism of Action The inhibitory mechanism has the potential to inhibit multiple modes of mast cell activation Mast cell inhibition by AK006 requires Fc-Fc𝛾 receptor interaction AK006 has high residence time due to minimal…
Slide 11: AK006 Displays High Levels of Mast Cell Inhibition in Preclinical Studies
AK006 Displays High levels of Mast Cell Inhibition in Preclinical Studies AK006 inhibits IgE-dependent and IgE-independent modes of mast cell activation *** p < 0.001 SOURCE: Korver, W. et al Allergy 2024; Allakos data on file
Slide 12: Systemic Administration of AK006 Prevents Ex-Vivo IgE Activation of Mast Cells
Systemic Administration of AK006 Prevents Ex-Vivo IgE Activation of Mast Cells Multiple dosing of AK006 provides more potent Mast Cell inhibition Mast Cell Activation N = 4-6 mice per group SOURCE: Allakos data on file
Slide 13: AK006 Protects Against Systemic Anaphylaxis in Humanized Mice
AK006 Protects Against Systemic Anaphylaxis in Humanized Mice Humanized Model of Anaphylactic Death AK006 protects mice from IgE-induced anaphylactic death SOURCE: Schanin, J et al. Communications Biology 2022.
Slide 14: AK006 Reduces Human Mast Cells via Antibody-Dependent Cellular Phagocytosis
AK006 Reduces Human Mast Cells via Antibody-Dependent Cellular Phagocytosis in Preclinical Studies In addition to mediating broad inhibition, AK006 can reduce mast cell numbers * p < 0.05; **** p < 0.0001; n=2 human donors SOURCE: Benet Z, et al. AAAAI 2023 Presentation; Allakos data on file
Slide 15: AK006 Inhibits IgE-Mediated Mast Cell Activation Similar to Remibrutinib
AK006 Inhibits IgE-Mediated Mast Cell Activation Similar to Remibrutinib n=5 human donors SOURCE: Allakos data on file
Slide 16: AK006 in Phase 1 Clinical Study in Healthy Volunteers and Chronic Spontaneous Urticaria
AK006 in Phase 1 Clinical Study in Healthy Volunteers and Chronic Spontaneous Urticaria
Slide 17: Phase 1 Study Design
AK006 Phase 1 Study Design Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts in Healthy Volunteers Randomized, double-blind, placebo-controlled Intravenous AK006 SAD: 5, 20, 80, 240, 720 mg MAD: 80, 240, 720 mg monthly Subcutaneous AK006 150 and 720 mg Planned CSU Cohort Randomiz
Slide 18: Subcutaneous AK006 has 77% Bioavailability
Subcutaneous AK006 has 77% Bioavailability SC and IV AK006 have good pharmacokinetic properties with a half life of 12-22 days
Slide 19: High Siglec-6 Occupancy is Observed at Low Doses
High Siglec-6 Occupancy is Observed at Low Doses Siglec-6 Receptor Occupancy (mean, %) Route Dose Cohort (mg) n S6 % Receptor Occupancy % Surface Siglec-6 Day 29† Baseline Day 29 Day 113* IV & SC PBO 19 0 2 2 103 SAD IV 5 7 0 45 - 82 20 6 0 92 - 68 80 6 0 96 - 133 240 6 0 94 93 162 720 6 0 101 94 13
Slide 20: AK006 was Well-Tolerated with a Favorable Safety Profile
AK006 was Well-Tolerated with a Favorable Safety Profile Single and multiple doses of IV AK006 and single doses of SC up to 720 mg were well-tolerated with a favorable safety profile. In the safety profile to date: No treatment emergent SAEs in subjects on AK006 There were no treatment emergent adve
Slide 21: AK006 for Chronic Spontaneous Urticaria
AK006 for Chronic Spontaneous Urticaria
Slide 22: AK006 May Inhibit Disease Driving Pathways in Urticaria
AK006 May Inhibit Disease Driving Pathways in Urticaria Activated mast cells drive the pathogenesis of urticaria via release of inflammatory mediators resulting in pruritis, vasodilation, and increased vascular permeability Blocking both IgE activation and IgE-independent mast cell activation could
Slide 23: Chronic Spontaneous Urticaria Opportunity
Chronic Spontaneous Urticaria Opportunity CSU affects up to 3 million adults in the U.S., with 2 million managed by a specialist (allergist or dermatologist)1,2 1. Maurer M, et al. Allergy. 2011 Mar;66(3):317-30. 2. Allakos allergist and dermatologist market research survey (N=208), Nov 2021. 3. Dec
Slide 24: Chronic Spontaneous Urticaria Landscape
Chronic Spontaneous Urticaria Landscape Drug Name MOA UAS7 Response Opportunity Xolair® (omalizumab) Anti-IgE mAb Dose Group1 150 mg 300 mg Placebo Placebo >50% of patients continue to have symptoms Black box for anaphylaxis1 UAS7 -14.4 (-48%) -20.8 (-66%) -8.0 (-26%) -8.0 (-26%) UAS7=0 15% 36% 9% 9
Slide 25: Financial Overview & Key Milestones
Financial Overview & Key Milestones
Slide 26: Data Catalysts and Expected Milestones
Data Catalysts and Expected Milestones Q2 2024: Report SAD and MAD safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 IV AK006 trial in healthy volunteers, including data to confirm Siglec-6 receptor occupancy in skin biopsy samples. Q2 2024: Initiate the randomized, do
Slide 27: Balance Sheet and IP Protection
Cash, Cash Equivalents and Investments in Marketable Securities as of December 31, 2023 $170.8 M – Estimated 2024 cash used in restructuring (lirentelimab closeout, severance and other costs) $30 M – Estimated 2024 cash used in ongoing business operations $55 to $60 M Estimated, Cash, Cash Equivalen